Insulet Corp. (PODD) Long-Term Debt
The long-term debt for Insulet Corp. (PODD) is $979.70 Million with a year-over-year change of -24.41%. Long-term debt includes bonds, term loans, mortgages, and other borrowings with maturities greater than one year. It represents the company's structural leverage.
PODD Long-Term Debt Chart
Reported annual fiscal-period values; no daily interpolation.
Current Long-Term Debt
$979.70M
$979.70 Million
Year-over-Year Change
-24.41%
vs. $1.30B prior year
Historical Data
24
Years of data available
Annual Long-Term Debt History
| Year | Long-Term Debt | YoY Change | % Change |
|---|---|---|---|
| 2025 | $979.70M | $-316.40M | -24.41% |
| 2024 | $1.30B | $-70.30M | -5.14% |
| 2023 | $1.37B | $-7.90M | -0.57% |
| 2022 | $1.37B | +$125.50M | +10.05% |
| 2021 | $1.25B | +$205.10M | +19.65% |
| 2020 | $1.04B | +$155.80M | +17.55% |
| 2019 | $887.90M | +$295.92M | +49.99% |
| 2018 | $591.98M | +$25.80M | +4.56% |
| 2017 | $566.17M | +$233.41M | +70.14% |
| 2016 | $332.77M | +$160.80M | +93.51% |
| 2015 | $171.97M | +$5.68M | +3.42% |
| 2014 | $166.28M | +$47.24M | +39.69% |
| 2013 | $119.04M | +$15.31M | +14.76% |
| 2012 | $103.73M | $-4.81M | -4.43% |
| 2011 | $108.54M | +$39.11M | +56.32% |
| 2010 | $69.43M | $-27.55M | -28.40% |
| 2009 | $96.98M | +$36.81M | +61.17% |
| 2008 | $60.17M | +$44.17M | +275.93% |
| 2007 | $16.01M | +$16.01M | — |
| 2006 | $0 | $-8.30M | -100.00% |
| 2005 | $8.30M | +$8.30M | — |
| 2004 | $0 | +$0 | — |
| 2003 | $0 | +$0 | — |
| 2002 | $0 | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy